title: Parameters of haemostasis during acute venous thrombosis.
abstract: Underlying disorders of the coagulation system such as inhibitor deficiencies or decreased fibrinolysis are common in patients suffering from venous thrombosis. They may lead to the necessity of a lifelong prophylaxis. Prompt diagnosis is obviously to the patients benefit. We investigated 22 patients suffering from venous thromboses for the inhibitors antithrombin III (ATIII), protein C, and protein S during the first 8 to 12 days after admission to hospital and in addition after withdrawal from anticoagulant treatment after several months. At the day of admission ATIII and protein C levels were comparable to those several months later, but after 2 days they shifted downward or upward, respectively. Protein S did not shift during the period of hospitalisation, but was initially slightly lower than several months later. For inhibitors the day of admission to hospital is most suitable to take the samples. About 50% of the patients still had elevated activation markers (prothrombin fragments F1+2, thrombin-antithrombin complex TAT, and D-dimers) after several months.
authors.affiliation: Dept. of Medicine, University Hospital, Würzburg, Germany.
authors.forename: W
authors.initials: W
authors.lastname: Reiter
authors.forename: H
authors.initials: H
authors.lastname: Ehrensberger
authors.forename: B
authors.initials: B
authors.lastname: Steinbrückner
authors.forename: F
authors.initials: F
authors.lastname: Keller
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000925:Anticoagulants / Q000627:therapeutic use; D000990:Antithrombin III / Q000032:analysis*; D001800:Blood Specimen Collection; D002097:C-Reactive Protein / Q000032:analysis; D003278:Contraceptives, Oral, Hormonal / Q000009:adverse effects; D005260:Female; D006487:Hemostasis; D006760:Hospitalization; D006801:Humans; D008297:Male; D008875:Middle Aged; D010447:Peptide Hydrolases / Q000032:analysis; D011486:Protein C / Q000032:analysis*; D017293:Protein S / Q000032:analysis*; D011655:Pulmonary Embolism / Q000097:blood / Q000188:drug therapy; D012008:Recurrence; D015912:Thrombolytic Therapy; D013924:Thrombophlebitis / Q000097:blood* / Q000188:drug therapy; D013997:Time Factors
chemical_list: D000925:Anticoagulants; D003278:Contraceptives, Oral, Hormonal; D011486:Protein C; D017293:Protein S; C046193:antithrombin III-protease complex; D000990:Antithrombin III; D002097:C-Reactive Protein; D010447:Peptide Hydrolases